Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Heinrich

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2012
Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort studyAndrea Rachow, Petra Clowes, Elmar Saathoff, et al.
The Lancet. Microbe|October 13, 2023
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trialsEmmanuel Musisi, Adam Wyness, Sahar Eldirdiri, et al.
Plos One|July 9, 2011
Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation studyAndrea Rachow, Alimuddin Zumla, Norbert Heinrich, et al.
The Journal of Infectious Diseases|March 27, 2012
Innovative trial designs are practical solutions for improving the treatment of tuberculosisPatrick P J Phillips, Stephen H Gillespie, Martin Boeree, et al.
BMC Medicine|March 24, 2016
A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Patrick P J Phillips, Kelly E Dooley, Stephen H Gillespie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2022
Tuberculosis Molecular Bacterial Load Assay Reveals Early Delayed Bacterial Killing in Patients With RelapseNyanda Elias Ntinginya, Abhishek Bakuli, Daniel Mapamba, et al.
PLOS Global Public Health|March 24, 2023
User perspectives and preferences on a novel TB LAM diagnostic (Fujifilm SILVAMP TB LAM)-a qualitative study in Malawi and ZambiaYannis Herrmann, Federica Lainati, María Del Mar Castro, et al.
PLOS Global Public Health|March 31, 2025
Prediction models for Mtb infection among adolescent and adult household contacts in high tuberculosis incidence settingsEdson Tawanda Marambire, Claire J Calderwood, Leyla Larsson, et al.
Plos One|November 27, 2013
miRNA signatures in sera of patients with active pulmonary tuberculosisPaolo Miotto, Grace Mwangoka, Ilaria C Valente, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2014
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populationsRuth Bowness, Martin J Boeree, Rob Aarnoutse, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2012
Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort studyAndrea Rachow, Petra Clowes, Elmar Saathoff, et al.
The Lancet. Microbe|October 13, 2023
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trialsEmmanuel Musisi, Adam Wyness, Sahar Eldirdiri, et al.
Plos One|July 9, 2011
Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation studyAndrea Rachow, Alimuddin Zumla, Norbert Heinrich, et al.
The Journal of Infectious Diseases|March 27, 2012
Innovative trial designs are practical solutions for improving the treatment of tuberculosisPatrick P J Phillips, Stephen H Gillespie, Martin Boeree, et al.
BMC Medicine|March 24, 2016
A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Patrick P J Phillips, Kelly E Dooley, Stephen H Gillespie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2022
Tuberculosis Molecular Bacterial Load Assay Reveals Early Delayed Bacterial Killing in Patients With RelapseNyanda Elias Ntinginya, Abhishek Bakuli, Daniel Mapamba, et al.
PLOS Global Public Health|March 24, 2023
User perspectives and preferences on a novel TB LAM diagnostic (Fujifilm SILVAMP TB LAM)-a qualitative study in Malawi and ZambiaYannis Herrmann, Federica Lainati, María Del Mar Castro, et al.
PLOS Global Public Health|March 31, 2025
Prediction models for Mtb infection among adolescent and adult household contacts in high tuberculosis incidence settingsEdson Tawanda Marambire, Claire J Calderwood, Leyla Larsson, et al.
Plos One|November 27, 2013
miRNA signatures in sera of patients with active pulmonary tuberculosisPaolo Miotto, Grace Mwangoka, Ilaria C Valente, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2014
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populationsRuth Bowness, Martin J Boeree, Rob Aarnoutse, et al.
Pageof 9